2016年，全球医药市场规模超过1万亿美元，医药研发成本不断攀升，小分子新药获批数量日益降低，抗肿瘤药物、孤儿药研发势头依旧不减。随着生物药专利悬崖逐渐显现，生物类似药崭露头角。遴选了2016年上市的部分重磅新药，盘点了抗感染、抗肿瘤、中枢神经系统等领域的新药研发进展，回顾了2016年国内药学领域的相关热点事件。
In 2016, the global pharmaceutical market size reached more than 1 trillion US dollars. In spite of the rise of pharmaceutical research & development cost and the decline of approval number of small molecular drugs, the research and development of anti-tumor drugs and orphan drugs remained robust last year. On the other hand, with the coming patent cliff of biological products, biosimilars were emerging. In this paper, we select some of the blockbusters in 2016, covering the frontiers of drug development for anti-infection, antitumor, central nervous system and other areas, and provide a review of 2016 domestic hotspots in pharmaceutical industry.
[1] The global use of medicines:Outlook through 2020[EB/OL].[2015-11-07]. http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/global-medicines-use-in-2020.
[2] Novel drug approvals for 2016[EB/OL].[2016-12-27]. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm483775.htm.
[3] 丙肝重大里程碑!吉利德全球首个泛基因型丙肝鸡尾酒Epclusa获美国和欧盟批准[EB/OL].[2016-12-27]. http://news.bioon.com/article/6685467.html.
[4] FDA Drug Databases:EPCLUSA (SOFOSBUVIR; VELPATASVIR)[EB/OL].[2016-12-27]. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208341.
[5] Gilead乙肝新药TAF在日本获批[EB/OL].[2016-12-20]. http://www.pharmcube.com/news/article/1942.
[6] FDA Drug Databases:VEMLIDY (TENOFOVIR ALAFENAMIDE FUMARATE)[EB/OL].[2016-12-27]. http://www.accessdata.fda.gov/scripts/cder/daf/in-dex.cfm?event=overview.process&ApplNo=208464.
[7] 禾木. 豪门Gilead竟被指控"利欲熏心"?TAF上市背后的故事[EB/OL].[2016-06-02]. http://mp.weixin.qq.com/s?__biz=MzA4MDA4MTIzMg==&mid=2653042160&idx=1&sn=0b711a851116662bbc739764fb39f9d1&scene=21#wechat_redirect.
[8] FDA批准Descovy,Gilead的第三个以TAF为基础的治疗HIV药物[EB/OL].[2016-04-05]. https://www.pharmacodia.com/web/i_c/detail_1_8a2d983753cb3fb70153e44e9eff05b5.html.
[9] FDA drug databases:Venclexta (Venetoclax)[EB/OL].[2016-12-27]. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process& varApplNo=208573.
[10] Charles. PPI靶点BCL-2的小分子抑制剂被FDA批准上市[EB/OL].[2016-04-20]. http://mp.weixin.qq.com/s?__biz=MzAwMDAzMTM4Mw==&mid=2650125321&idx=1&sn=59a64beca7cf09c4e1500fba29979093.
[11] 喜讯!罗氏抗PD-L1免疫疗法Tecentriq获美国FDA批准治疗晚期非小细胞肺癌(NSCLC)[EB/OL].[2016-10-20]. http://news.bioon.com/article/6691397.html.
[12] 超重磅!罗氏PD-L1免疫疗法Tecentriq(atezolizumab)获FDA加速批准,成功跻身PD-1/PD-L1商业圈[EB/OL].[2016-05-19]. http://news.bioon. com/article/6683052.html.
[13] 40年重大突破!欧盟批准礼来抗癌药Lartruvo联合阿霉素用于软组织肉瘤(STS)一线治疗[EB/OL].[2016-11-14]. http://news.bioon.com/article/6692518.html.
[14] Lartruvo:Designed to disrupt the signal[EB/OL].[2016-12-27]. https://www.lartruvo.com/hcp/mechanism-of-action.
[15] Michael H. Clinical development success rates for investigational drugs[J]. Nature Biotechnology, 2014, 32(1):40-51.
[16] FDA drug databases:Briviact(Brivaracetam)[EB/OL].[2016-12-27]. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process& varApplNo=205836.
[17] UCB的新一代抗癫痫药物Briviact® (Brivaracetam,布瓦西坦)获得EU批准[EB/OL].[2016-01-21]. https://www.pharmacodia.com/web/i_c/getInforma-tionById?id=8a2d983752154efa01525e1f342700df&languageType=zh_CN.
[18] Armstrong. Zinbryta、Zenapax对比分析:看达利珠单抗老药新用如何创新[EB/OL].[2016-06-01]. http://mp.weixin.qq.com/s?src=3×tamp=1483005429&ver=1&signature=B7q0QMAqUA5jLujN9bYYiDreuD0LPL0KeU0RAJAYT8o-WR8Szfc53r*6MOPb7ze8jGBZkB6E-wzxBZ6qWrAVMlDsb-zuIY4yqwVi5GBa-4JEe1ebPUPIb45qyhcgMZAb957iDC40li4IDkr5aJ9oE4kIpRB7d4Wb2xd*KBCa3tdk=.
[19] 百健艾迪Zinbryta关键III期击败全球TOP2药物Avonex[EB/OL].[2014-09-13]. http://news.bioon.com/article/6658717.html.
[20] 罕见病重磅消息!全球首个脊髓性肌萎缩症(SMA)治疗药物Spinraza获美国FDA批准[EB/OL].[2016-12-26]. http://news.bioon.com/article/6696232.html.
[21] Si L, Xu H, Zhou X, et al. Generation of influenza A viruses as live but replication-incompetent virus vaccines[J]. Science, 2016, 354(6316):1170-1173.
[22] 吴非. 北大发现通用疫苗制备方法,或能应对几乎所有病毒[EB/OL].[2016-12-06]. http://www.huanqiukexue.com/a/qianyan/shengwu__yixue/2016/1206/26839.html.
[23] 仿制药一致性评价进入评价核查阶段[EB/OL].[2016-12-23]. http://mp.weixin.qq.com/s?src=3×tamp=1483079982&ver=1&signature=rFTShy-Ry4ThS1JDtqMthq6hZVOTTbaR1GiHXcAALMWh88fXKvXOm*iWtZJ83FCeNOpvsc8PFiSQIZNZ423KDrSqq3HmHg0mM6sw1uwMTIoHk2NrxMbTNpSjq3tejJS83pOwXrM9EAHFLp2io9PzqWh9vY0HW2m4NBGNbdZymA0k=.
[24] 全国人大常委会通过中国中医药法[EB/OL].[2016-12-25]. http://ku6.chinanews.com/gn/2016/12-25/8104313.shtml.
